Biotechnology
Compare Stocks
2 / 10Stock Comparison
PHGE vs LSTA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
PHGE vs LSTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.01B | $29M |
| Revenue (TTM) | $0.00 | $170K |
| Net Income (TTM) | $-36M | $-17M |
| Gross Margin | — | 91.2% |
| Operating Margin | — | -107.1% |
| Total Debt | $1M | $0.00 |
| Cash & Equiv. | $5M | $16M |
PHGE vs LSTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BiomX Inc. (PHGE) | 100 | 0.1 | -99.9% |
| Lisata Therapeutics… (LSTA) | 100 | 11.3 | -88.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PHGE vs LSTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PHGE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.14
- EPS growth 20.6%
- Lower volatility, beta 1.14, current ratio 0.87x
LSTA is the clearest fit if your priority is long-term compounding.
- -96.8% 10Y total return vs PHGE's -100.0%
- +40.4% vs PHGE's -94.3%
- -70.8% ROA vs PHGE's -80.4%, ROIC -229.7% vs -444.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -62.3% revenue growth vs LSTA's -83.0% | |
| Quality / Margins | -0.7% margin vs LSTA's -97.6% | |
| Stability / Safety | Beta 1.14 vs LSTA's 1.17 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +40.4% vs PHGE's -94.3% | |
| Efficiency (ROA) | -70.8% ROA vs PHGE's -80.4%, ROIC -229.7% vs -444.8% |
PHGE vs LSTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PHGE vs LSTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
LSTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LSTA and PHGE operate at a comparable scale, with $170,000 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $170,000 |
| EBITDAEarnings before interest/tax | -$28M | -$18M |
| Net IncomeAfter-tax profit | -$36M | -$17M |
| Free Cash FlowCash after capex | -$26M | -$16M |
| Gross MarginGross profit ÷ Revenue | — | +91.2% |
| Operating MarginEBIT ÷ Revenue | — | -107.1% |
| Net MarginNet income ÷ Revenue | — | -97.6% |
| FCF MarginFCF ÷ Revenue | — | -94.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -90.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.1% | +40.0% |
Valuation Metrics
LSTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.0B | $29M |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $13M |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -1.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 173.02x |
| Price / BookPrice ÷ Book value/share | — | 1.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
LSTA leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
LSTA delivers a -85.5% return on equity — every $100 of shareholder capital generates $-85 in annual profit, vs $-3 for PHGE. On the Piotroski fundamental quality scale (0–9), PHGE scores 2/9 vs LSTA's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -2.7% | -85.5% |
| ROA (TTM)Return on assets | -80.4% | -70.8% |
| ROICReturn on invested capital | -4.4% | -2.3% |
| ROCEReturn on capital employed | -66.6% | -82.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$4M | -$16M |
| Cash & Equiv.Liquid assets | $5M | $16M |
| Total DebtShort + long-term debt | $1M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -33.64x | — |
Total Returns (Dividends Reinvested)
LSTA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LSTA five years ago would be worth $1,417 today (with dividends reinvested), compared to $5 for PHGE. Over the past 12 months, LSTA leads with a +40.4% total return vs PHGE's -94.3%. The 3-year compound annual growth rate (CAGR) favors LSTA at -0.4% vs PHGE's -77.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -71.1% | +64.8% |
| 1-Year ReturnPast 12 months | -94.3% | +40.4% |
| 3-Year ReturnCumulative with dividends | -98.9% | -1.2% |
| 5-Year ReturnCumulative with dividends | -99.9% | -85.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -77.4% | -0.4% |
Risk & Volatility
Evenly matched — PHGE and LSTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
PHGE is the less volatile stock with a 1.14 beta — it tends to amplify market swings less than LSTA's 1.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LSTA currently trades 63.7% from its 52-week high vs PHGE's 4.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 1.17x |
| 52-Week HighHighest price in past year | $14.71 | $5.07 |
| 52-Week LowLowest price in past year | $0.61 | $1.81 |
| % of 52W HighCurrent price vs 52-week peak | +4.2% | +63.7% |
| RSI (14)Momentum oscillator 0–100 | 21.4 | 35.1 |
| Avg Volume (50D)Average daily shares traded | 193K | 76K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $38.00 | — |
| # AnalystsCovering analysts | 5 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
LSTA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
PHGE vs LSTA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PHGE or LSTA a better buy right now?
Analysts rate BiomX Inc.
(PHGE) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PHGE or LSTA?
Over the past 5 years, Lisata Therapeutics, Inc.
(LSTA) delivered a total return of -85. 8%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: LSTA returned -96. 8% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PHGE or LSTA?
By beta (market sensitivity over 5 years), BiomX Inc.
(PHGE) is the lower-risk stock at 1. 14β versus Lisata Therapeutics, Inc. 's 1. 17β — meaning LSTA is approximately 3% more volatile than PHGE relative to the S&P 500.
04Which is growing faster — PHGE or LSTA?
On earnings-per-share growth, the picture is similar: BiomX Inc.
grew EPS 20. 6% year-over-year, compared to 20. 4% for Lisata Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PHGE or LSTA?
BiomX Inc.
(PHGE) is the more profitable company, earning 0. 0% net margin versus -97. 6% for Lisata Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0. 0% versus -107. 1% for LSTA. At the gross margin level — before operating expenses — LSTA leads at 14. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PHGE or LSTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PHGE or LSTA better for a retirement portfolio?
For long-horizon retirement investors, BiomX Inc.
(PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). Both have compounded well over 10 years (PHGE: -100. 0%, LSTA: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PHGE and LSTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.